Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Epigenome-based cancer risk prediction: rationale, opportunities and challenges

Open access
on behalf of the FORECEE (4C) Consortium, Widschwendter, Martin, Jones, Allison, Evans, Iona, Reisel, Daniel, Dillner, Joakim, Sundström, Karin, Steyerberg, Ewout W., Vergouwe, Yvonne, Wegwarth, Odette, Rebitschek, Felix G., Siebert, Uwe, Sroczynski, Gaby, de Beaufort, Inez D., Bolt, Ineke, Cibula, David, Zikan, Michal, Bjørge, Line, Colombo, Nicoletta, Harbeck, Nadia, Dudbridge, Frank, Tasse, Anne-Marie, Knoppers, Bartha M., Joly, Yann, Teschendorff, Andrew E., Pashayan, Nora · 2018 · Nature Reviews Clinical Oncology

Abstract

The incidence of cancer is continuing to rise and risk-tailored early diagnostic and/or primary prevention strategies are urgently required. The ideal risk-predictive test should: integrate the effects of both genetic and nongenetic factors and aim to capture these effects using an approach that is both biologically stable and technically reproducible; derive a score from easily accessible biological samples that acts as a surrogate for the organ in question; and enable the effectiveness of risk-reducing measures to be monitored. Substantial evidence has accumulated suggesting that the epigenome and, in particular, DNA methylation-based tests meet all of these requirements. However, the development and implementation of DNA methylation-based risk-prediction tests poses considerable challenges. In particular, the cell type specificity of DNA methylation and the extensive cellular heterogeneity of the easily accessible surrogate cells that might contain information relevant to less accessible tissues necessitates the use of novel methods in order to account for these confounding issues. Furthermore, the engagement of the scientific community with health-care professionals, policymakers and the public is required in order to identify and address the organizational, ethical, legal, social and economic challenges associated with the routine use of epigenetic testing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2018.30

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 160

Metadata

Authors
on behalf of the FORECEE (4C) Consortium, Widschwendter, M., Jones, A., Evans, I., Reisel, D., Dillner, J., Sundström, K., Steyerberg, E. W., Vergouwe, Y., Wegwarth, O., Rebitschek, F. G., Siebert, U., Sroczynski, G., de Beaufort, I. D., Bolt, I., Cibula, D., Zikan, M., Bjørge, L., Colombo, N., Harbeck, N., Dudbridge, F., Tasse, A.-M., Knoppers, B. M., Joly, Y., Teschendorff, A. E., & Pashayan, N.
Venue
Nature Reviews Clinical Oncology
Published
2018-02-27
Volume
15
Issue
5
Pages
292-309
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W2789727733
Cited by
160
References
49
FWCI
1.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epigenome-based cancer risk prediction: rationale, opportunities and challenges. https://app.cochat.ai/papers/10.1038/nrclinonc.2018.30
The paper
on behalf of the FORECEE (4C) Consortium, Widschwendter, M., Jones, A., Evans, I., Reisel, D., Dillner, J., Sundström, K., Steyerberg, E. W., Vergouwe, Y., Wegwarth, O., Rebitschek, F. G., Siebert, U., Sroczynski, G., de Beaufort, I. D., Bolt, I., Cibula, D., Zikan, M., Bjørge, L., Colombo, N., . . . Pashayan, N. (2018). Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nature Reviews Clinical Oncology. https://doi.org/10.1038/nrclinonc.2018.30

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.